LEQVIO is for LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy.1
of cardiovascular events in patients who failed to reach LDL-C goal6†
The effect of LEQVIO® on cardiovascular morbidity and mortality has not been determined.
*An event is defined as acute coronary syndrome (unstable angina, STEMI, or NSTEMI).7
†Based on study (n= 38,110,734) data that evaluated the annual cardiovascular event rates in a subset of guideline-defined high-risk patients of the Family Heart Database which comprises diagnostic, procedure, lab, and prescription data from claims in the US from 2012 to 2021.6
†Based on study (n= 38,110,734) data that evaluated the annual cardiovascular event rates in a subset of guideline-defined high-risk patients of the Family Heart Database which comprises diagnostic, procedure, lab, and prescription data from claims in the US from 2012 to 2021.6
Many patients struggle to adhere to self-administered treatments
of patients discontinue statins within 1 year2-5
of patients discontinue PCSK9 mAbs within 6 months8,9‡§
‡From an analysis of a large IQVIA open claims dataset of patients (N=72,001) between January 2021 and December 2021.9
§In a retrospective cohort study of pharmacy and health plan claims of patients who initiated PCSK9 mAbs (N=13,151) between January 1, 2016, and June 30, 2016, who were followed for a minimum of 6 months after their first prescription fill. Discontinuation was defined as the gap of 60 days or more between the last day of supply of one prescription and the start of the next prescription. Specific reasons for discontinuation were unknown; however, it could have been due to poor tolerability, noncompliance, unwillingness to perform injections, and insurance or cost issues. Gaps in therapy were derived from actual prescription fill data.8
§In a retrospective cohort study of pharmacy and health plan claims of patients who initiated PCSK9 mAbs (N=13,151) between January 1, 2016, and June 30, 2016, who were followed for a minimum of 6 months after their first prescription fill. Discontinuation was defined as the gap of 60 days or more between the last day of supply of one prescription and the start of the next prescription. Specific reasons for discontinuation were unknown; however, it could have been due to poor tolerability, noncompliance, unwillingness to perform injections, and insurance or cost issues. Gaps in therapy were derived from actual prescription fill data.8
For LDL-C reduction when diet and statin are not enough.1
Michael | Patient with Coronary Artery Disease (CAD)
Recent Event: NSTEMI <12 months ago
Recent Procedure: PCI
LDL-C Level: 105 mg/dL
Additional CV Risk Factors: Hyperlipidemia, type 2 diabetes, hypertension
Current LDL-C Treatment: High-intensity statin
When statins aren’t enough, Look to LEQVIO
*An event is defined as acute coronary syndrome (unstable angina, STEMI, or NSTEMI).6
THERE’S MORE TO KNOW ABOUT LEQVIO
See what LEQVIO can do for patients like yours
CAD, coronary artery disease; CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; mAbs, monoclonal antibodies; NSTEMI, non–ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PCSK9, proprotein convertase subtilisin/kexin type 9; STEMI, ST-elevation myocardial infarction.